2024
Combined BET and MEK Inhibition synergistically suppresses melanoma by targeting YAP1
Hu R, Hou H, Li Y, Zhang M, Li X, Chen Y, Guo Y, Sun H, Zhao S, Liao M, Cao D, Yan Q, Chen X, Yin M. Combined BET and MEK Inhibition synergistically suppresses melanoma by targeting YAP1. Theranostics 2024, 14: 593-607. PMID: 38169595, PMCID: PMC10758063, DOI: 10.7150/thno.85437.Peer-Reviewed Original ResearchConceptsMEK inhibitor resistanceMEK inhibitor trametinibTrametinib treatmentInhibitor resistanceInhibitor trametinibMelanoma patientsYAP1 expressionMEK inhibitionBRAF-mutant melanoma patientsResistance to MEK inhibitionYAP1 inhibitionResistance to trametinibMelanoma growth <i>inInhibition of BRD4Trametinib resistanceAntitumor effectMelanoma growthTrametinibNHWD-870YAP1 inhibitorDrug resistanceMelanomaMelanoma samplesMelanoma cellsBRD4 depletion
2023
Single cell profiling of tumour biopsies and heterogeneity in response of dedifferentiated melanoma.
Lim E, Lin Y, Pedersen B, Stewart A, Scolyer R, Long G, Yang J, Rizos H. Single cell profiling of tumour biopsies and heterogeneity in response of dedifferentiated melanoma. JCO Global Oncology 2023, 9: 64-64. DOI: 10.1200/go.2023.9.supplement_1.64.Peer-Reviewed Original ResearchResistance to MAPK inhibitionPro-inflammatory IL-6BRAF/MEK inhibitorsIL-6MAPK inhibitionTumor biopsiesAdvanced BRAF V600-mutant melanomaResponse to second-line treatmentTreated with immune checkpoint inhibitorsDT treatmentBRAF-mutant melanoma patientsResponse to MAPK inhibitionMelanoma cellsBRAF V600-mutant melanomaV600-mutant melanomaImmune checkpoint inhibitorsSecond-line treatmentTNFA signalingEx vivo treatmentElevated IL-6Increased IL-6Treated ex vivoDifferentiation stateImmune cell proportionsProportion of melanoma cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply